BI-RA-260

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBI-RA-260
Drug Alias NameBI-RA-260
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukocyte elastase inhibitors
TargetsLeukocyte elastase
Therapy Area/IndicationsLower Urinary Tract SymptomsEmphysemaCystic Fibrosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Active IndicationsN/A
Inactive IndicationsLower Urinary Tract SymptomsEmphysemaCystic Fibrosis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A